We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1B
AUM Growth
+$73.5M
Cap. Flow
-$38M
Cap. Flow %
-3.79%
Top 10 Hldgs %
34.85%
Holding
100
New
15
Increased
28
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$17.5M
2
MDT icon
Medtronic
MDT
+$16.5M
3
TMO icon
Thermo Fisher Scientific
TMO
+$16M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$11.2M
5
RPRX icon
Royalty Pharma
RPRX
+$7.69M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$24.6M
2
LLY icon
Eli Lilly
LLY
+$12.8M
3
CVS icon
CVS Health
CVS
+$11.6M
4
ELV icon
Elevance Health
ELV
+$11.6M
5
MCK icon
McKesson
MCK
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
1
Medtronic
MDT
$109B
$48.7M 4.86%
591,000
+216,000
+58% +$16.5M
LLY icon
2
Eli Lilly
LLY
$1.02T
$45.5M 4.54%
78,005
-21,995
-22% -$12.8M
BSX icon
3
Boston Scientific
BSX
$69.5B
$43.4M 4.33%
750,000
+50,000
+7% +$2.67M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$121B
$38.7M 3.86%
95,000
+18,500
+24% +$6.83M
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$34.3M 3.42%
39,000
-1,000
-3% -$823K
HCA icon
6
HCA Healthcare
HCA
$87.2B
$29.5M 2.95%
109,000
+26,000
+31% +$6.43M
UNH icon
7
UnitedHealth
UNH
$376B
$28.4M 2.84%
54,000
+8,000
+17% +$4.27M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.6B
$27.2M 2.72%
282,500
-97,500
-26% -$8.63M
SWAV
9
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$26.7M 2.67%
140,000
+59,000
+73% +$11.2M
THC icon
10
Tenet Healthcare
THC
$20.5B
$26.6M 2.65%
351,630
+16,630
+5% +$1.05M
ABBV icon
11
AbbVie
ABBV
$443B
$25.9M 2.59%
167,000
+17,000
+11% +$2.48M
ABT icon
12
Abbott
ABT
$183B
$22.6M 2.25%
205,000
-56,675
-22% -$5.66M
COO icon
13
Cooper Companies
COO
$14.1B
$22.1M 2.21%
234,000
-6,000
-3% -$503K
ISRG icon
14
Intuitive Surgical
ISRG
$127B
$21.4M 2.14%
63,500
-4,000
-6% -$1.19M
MCK icon
15
McKesson
MCK
$100B
$21.3M 2.13%
46,000
-25,000
-35% -$11.4M
GILD icon
16
Gilead Sciences
GILD
$162B
$21M 2.1%
259,000
+25,000
+11% +$1.95M
COR icon
17
Cencora
COR
$60.6B
$19.7M 1.97%
96,000
-23,000
-19% -$4.49M
DHR icon
18
Danaher
DHR
$137B
$18M 1.8%
78,000
+10,320
+15% +$2.2M
HUM icon
19
Humana
HUM
$43.7B
$17.9M 1.79%
39,083
-9,917
-20% -$4.89M
TMO icon
20
Thermo Fisher Scientific
TMO
$213B
$17.8M 1.78%
33,500
+33,000
+6,600% +$16M
PFE icon
21
Pfizer
PFE
$143B
$16.7M 1.67%
+580,000
New +$17.5M
MRK icon
22
Merck
MRK
$322B
$16.1M 1.61%
147,500
-42,500
-22% -$4.41M
NTRA icon
23
Natera
NTRA
$38.3B
$15.3M 1.53%
245,000
-21,769
-8% -$1.09M
JAZZ icon
24
Jazz Pharmaceuticals
JAZZ
$15.9B
$15.2M 1.52%
123,634
-20,000
-14% -$2.5M
BIIB icon
25
Biogen
BIIB
$30B
$15.2M 1.52%
58,672
+2,172
+4% +$533K
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rhenman & Partners Asset Management held 100 positions worth $1B, up 7.9% from $928M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $38M in Q4 2023, closing 15 positions and reducing 32 holdings. Its most notable exit was Becton Dickinson, an estimated $24.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Pfizer worth $16.7M.

  • Rhenman & Partners Asset Management's largest Q4 2023 buy was Pfizer: 580,000 shares worth $16.7M.
  • Rhenman & Partners Asset Management added most to Medtronic in Q4 2023, an estimated $16.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2023 reduction was Eli Lilly, cutting an estimated $12.8M.
  • Rhenman & Partners Asset Management fully exited Becton Dickinson in Q4 2023, selling an estimated $24.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1B portfolio in Q4 2023.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 15 in Q4 2023.
  • Rhenman & Partners Asset Management's portfolio value rose 7.9% quarter-over-quarter to $1B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.